StreetInsider.com News Articles

Lucid Capital Markets Starts Tvardi Therapeutics Inc (TVRD) at Buy

Tue, 08 Sep 2026 06:37:19 -0400

(Updated - September 8, 2026 6:37 AM EDT)

Lucid Capital Markets analyst Elemer Piros initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $14.00.

The analyst comments "The company’s first-generation molecule, TTI-101, provided important early validation of the platform, demonstrating systemic exposure, human tumor target engagement and preliminary antitumor activity. However, the subsequent Phase 2 REVERT IPF study failed to demonstrate meaningful clinical efficacy, materially weakening the original fibrosis thesis. Tvardi has since reset its strategy around TTI-109, a next-generation prodrug of TTI-101, with ulcerative colitis (UC) selected as its lead indication. We view

Lucid Capital Markets Starts Tvardi Therapeutics Inc (TVRD) at Buy

Tue, 08 Sep 2026 06:37:19 -0400

(Updated - September 8, 2026 6:37 AM EDT)

Lucid Capital Markets analyst Elemer Piros initiates coverage on Tvardi Therapeutics Inc (NASDAQ: TVRD) with a Buy rating and a price target of $14.00.

Tvardi Therapeutics to Participate in Upcoming Investor Events

Wed, 26 Aug 2026 08:00:00 -0400

HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:

Wells Fargo 21st Annual Healthcare Conference
Format: 1-on-1 Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, September 10, 2026
Time: 10:55 AM ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company Presentation and 1-on-1 Meetings
Date: Monday, September

Tvardi Therapeutics to Participate in Upcoming Investor Events

Wed, 26 Aug 2026 08:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference
Format: 1-on-1 Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, September 10, 2026
Time: 10:55 AM ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company Presentation and 1-on-1 Meetings
Date: Monday, September

Tvardi Therapeutics to Participate in Upcoming Investor Events

Wed, 26 Aug 2026 08:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference
Format: 1-on-1 Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, September 10, 2026
Time: 10:55 AM ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company Presentation and 1-on-1 Meetings
Date: Monday, September

Tvardi Therapeutics to Participate in Upcoming Investor Events

Wed, 26 Aug 2026 08:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference
Format: 1-on-1 Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, September 10, 2026
Time: 10:55 AM ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Format: Company Presentation and 1-on-1 Meetings
Date: Monday, September

H.C. Wainwright Reiterates Buy Rating on Tvardi Therapeutics Inc (TVRD)

Mon, 17 Aug 2026 06:50:27 -0400

H.C. Wainwright analyst Sara Nik reiterated a Buy rating and $9.00 price target on Tvardi Therapeutics Inc (NASDAQ: TVRD).

The analyst commented: "Tvardi announced 2Q26 financial results and provided a business update. In our view the quarter reset the company's strategic frame around two assets and one key upcoming event. Key updates include: The company reported topline results from the healthy volunteer study of TTI-109, its next-generation STAT3 inhibitor. Per the company, TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and, across the active dose range, produced reductions in cellular and humoral immune populations that the company notes are known to correlate

Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c

Fri, 14 Aug 2026 07:31:31 -0400

Tvardi Therapeutics (NASDAQ: TVRD) reported Q2 EPS of ($0.69), $0.01 better than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Tvardi Therapeutics (TVRD) click here.

Form 10-Q Tvardi Therapeutics, For: Jun 30

Fri, 14 Aug 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26924491.html

Form 10-Q Tvardi Therapeutics, For: Jun 30

Fri, 14 Aug 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26924491.html

Form 8-K Tvardi Therapeutics, For: Aug 14

Fri, 14 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26924473.html

Form 8-K Tvardi Therapeutics, For: Aug 14

Fri, 14 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26924473.html

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Fri, 14 Aug 2026 07:00:00 -0400

Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations

Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Fri, 14 Aug 2026 07:00:00 -0400

Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Fri, 14 Aug 2026 07:00:00 -0400

Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Fri, 14 Aug 2026 07:00:00 -0400

Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026